GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.

11/11/2026, 1:00 PM • GlobeNewswire

Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.

11/11/2026, 1:00 PM • GlobeNewswire

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas, a clinical-stage biotech company specializing in protein degradation therapies, announced management participation in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company will present preliminary clinical data from early monotherapy dose escalation cohorts of ARV-393 (Zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology Annual Meeting, including safety, pharmacokinetics, and pharmacodynamics data.

11/11/2026, 7:00 AM • GlobeNewswire

3 Magnificent Dividend Stocks Yielding 4% or More to Buy in November

The article highlights three blue-chip dividend stocks offering yields above 4% with strong dividend coverage and growth potential: PepsiCo (54-year dividend growth streak, 4.2% yield), Pfizer (16-year consecutive raises, 5.8% yield), and AT&T (sustainable 47% payout ratio, trading at low valuation multiples). All three are positioned to maintain their dividends despite current headwinds.

11/10/2026, 8:30 PM • The Motley Fool

Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight

The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.

11/10/2026, 1:00 PM • GlobeNewswire

Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock

Pfizer has outperformed the broader market in 2026, rising 18% year-to-date and hitting a new 52-week high. Despite the stock's gains, it remains undervalued with a forward P/E ratio of just 10. The company's recently launched and acquired products showed impressive 32% growth in the latest quarter, demonstrating successful portfolio expansion. With a 5.9% dividend yield and strong drug pipeline, Pfizer presents a compelling long-term buy-and-hold opportunity for investors.

11/10/2026, 6:00 AM • The Motley Fool

Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access

Trogenix Ltd, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its next phase of growth. Young brings 35+ years of pharmaceutical leadership experience from Pfizer, while Murray brings capital markets expertise from Goldman Sachs and Orca Bio. The appointments follow breakthrough pre-clinical data published in Nature and the dosing of the first patient in the Phase I/II ADePT trial for glioblastoma.

11/10/2026, 2:00 AM • GlobeNewswire

Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.

11/09/2026, 9:45 AM • The Motley Fool

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.

11/09/2026, 5:00 AM • The Motley Fool

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

While Eli Lilly dominates the GLP-1 weight-loss drug market and Novo Nordisk struggles to regain ground, Pfizer is positioning itself as a surprise contender. After dropping its original GLP-1 candidate, Pfizer acquired an alternative drug in development and is now running 10 late-stage trials. The company's key differentiator is a monthly injection option, which could offer greater convenience than competitors' weekly or daily dosing. With a high dividend yield of 5.5% and an inflection point potentially closer than Wall Street believes, Pfizer may represent an overlooked opportunity for long-term dividend investors.

11/07/2026, 4:15 PM • The Motley Fool

The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?

Invesco Pharmaceuticals ETF (PJP) delivers higher returns (32.8% over one year, 10.7% CAGR since 2021) with concentrated U.S. pharma exposure but higher fees (0.58%), while iShares Global Healthcare ETF (IXJ) offers broader global diversification across 109 holdings, lower costs (0.38%), and higher dividend yield (1.3%), making it suitable for cost-conscious investors seeking diversified healthcare exposure.

11/07/2026, 9:15 AM • The Motley Fool

Pfizer: 3 Key Takeaways for Long-Term Investors

Pfizer raised its 2026 revenue guidance to $62-64 billion, driven by strong performance from launched and acquired products with 32% operational revenue growth in Q3. The company is implementing $7.2 billion in cost-saving initiatives to offset upcoming patent expirations on key drugs. Management projects high single-digit revenue growth from 2028-2033, contingent on successfully converting late-stage oncology and obesity treatment trials into commercial revenue.

11/04/2026, 8:47 AM • The Motley Fool

Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?

Pfizer reported strong Q3 results, beating analyst expectations with $16.6B in revenue (vs. $15.9B forecast) and $0.87 EPS (vs. $0.73 expected). The company raised full-year guidance and highlighted 32% growth from launched and acquired products. Trading at a modest 10x forward P/E with a 5.6% dividend yield, the stock may be positioned for further gains despite being down 30% over five years due to declining COVID-related revenues.

11/03/2026, 8:30 AM • The Motley Fool

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are revolutionizing healthcare with massive growth potential. Beyond weight loss and diabetes, research shows these drugs may treat cardiovascular, kidney, liver, and other diseases, with emerging evidence of anti-aging benefits. Morgan Stanley forecasts the obesity drug market will reach $190 billion by 2035, but the author believes this is understated given untapped international markets and expanding use cases.

11/02/2026, 9:00 AM • The Motley Fool

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

10/28/2026, 1:00 PM • GlobeNewswire